Other Clinical Trial - NCCH2006/MK010 Trial (FORTUNE Trial)

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03426254` - Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors	Phase 1
Completed	`NCT01285453` - Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors	Phase 1
Completed	`NCT01286987` - Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors	Phase 1

See also

Status

Clinical Trial

Phase

Withdrawn

NCT03426254 - Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Phase 1

Completed

NCT01285453 - Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

Phase 1

Completed

NCT01286987 - Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04962867
Study type	Interventional
Source	National Cancer Center, Japan
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 15, 2021
Completion date	December 31, 2024

NCCH2006/MK010 Trial (FORTUNE Trial)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms